Alternative Medicine

Wherever did Paul Smaglik get the idea that the boost in the National Institutes of Health's Office of Alternative Medicine (OAM) budget to $20 million was "unexpected" (P. Smaglik, "Office of Alternative Medicine Gets Unexpected Boost," The Scientist, Nov. 10, 1997, page 7)? In my opinion it was coldly calculated. No one, not even Sen. Tom Harkin (D-Iowa), would have expected Congress to give OAM institute status and a budget of $200 million. But by demanding just that and forcing the Congress

Written bySaul Green
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wherever did Paul Smaglik get the idea that the boost in the National Institutes of Health's Office of Alternative Medicine (OAM) budget to $20 million was "unexpected" (P. Smaglik, "Office of Alternative Medicine Gets Unexpected Boost," The Scientist, Nov. 10, 1997, page 7)? In my opinion it was coldly calculated. No one, not even Sen. Tom Harkin (D-Iowa), would have expected Congress to give OAM institute status and a budget of $200 million. But by demanding just that and forcing the Congress to turn down his request, Harkin put his buddies on the congressional conference committee in the position of having to mollify him with an agreeable alternative. That turned out to be an increase of OAM's annual budget to $20 million rather than a reduction to $7.5 million.

James Gordon's explanation in the article that research couldn't be done by OAM because it was institutionally shackled by other NIH ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies